Tom Rönnlund appointed new CEO of Probi

The Board of Probi has appointed Tom Rönnlund as CEO of Probi. Tom has more than 20 years’ experience working in sales, marketing and general management positions in the healthcare industry. Currently he serves as CEO for Norwegian listed company Navamedic ASA. Tom Rönnlund starts his assignment as CEO for Probi at the latest by the 1st of January, 2019.

Tom joined Navamedic ASA in 2015 as CEO and has led the transformation of the company through geographical expansion, significant new partnerships and focus on driving growth in higher margin product segments. Navamedic ASA is a stock-listed Norwegian pharmaceutical and medtech company, marketing products to patients, hospitals and pharmacies.

Prior to joining Navamedic ASA, Tom Rönnlund has held several positions in sales, marketing and general management at IQVIA (formerly IMS Health) and in international biopharmaceutical companies such as Bristol-Myers Squibb and Eli Lilly. Tom holds a master’s degree in business administration and Economics from Stockholm University.

“I´m confident that Tom Rönnlund, as new leader of the Probi team, who already did a great job until now, will be able to take Probi to the next level of innovation and profitable growth, by always keeping science as our main asset. I also take this opportunity to thank Ole Sogaard Andersen who did an excellent job during the interim period.”, says Chairman of the Board Jean-Yves Parisot.

“I am very excited to join Probi, a research-driven company with scientifically proven products and a team passionate about helping people live healthier lives, an important focus for me personally. The company is in a great position to expand through organic and acquisition-driven growth in a dynamic and fast-paced global market.”, says Tom Rönnlund.

This information is information that Probi AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 1 October 2018 at 8.45 CET.

FOR FURTHER INFORMATION, CONTACT:
Jean-Yves Parisot, Chairman of the Board, Probi, tel +33 670 48 0684, e-mail: ir@probi.com

ABOUT PROBI
Probi AB is a Swedish publicly traded bioengineering company. The vision of Probi is to help people live healthier lives by delivering effective and well-documented probiotics, with proven health benefits based on scientific research. Founded by scientists in Sweden in 1991, Probi is a multinational company with four sites, active in more than 40 markets around the world and holding over 400 patents worldwide. In 2017, Probi had net sales of MSEK 612. The Probi share is listed on Nasdaq Stockholm, Mid Cap. Probi has about 5,000 shareholders. Read more at www.probi.com. 

Tags:

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links